You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,159,683


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,159,683 protect, and when does it expire?

Patent 10,159,683 protects DEXYCU KIT and is included in one NDA.

This patent has twelve patent family members in eight countries.

Summary for Patent: 10,159,683
Title:Use of sustained release dexamethasone in post-cataract surgery inflammation
Abstract: The present embodiments provide for a treatment regimen and use of a short-term sustained release liquid formulation of dexamethasone in citrate, wherein a single administration of a minute dosage form into the anterior chamber of the eye provides for anti-inflammatory therapy following cataract surgery.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), White; William S. (Birmingham, AL), Hu; Mae W. (Los Altos Hills, CA), Huang; Glenn T. (Fremont, CA), Karasina; Faina (Mountain View, CA)
Assignee: ICON BIOSCIENCE, INC. (Watertown, MA)
Application Number:16/018,931
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery; Device; Dosage form;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of U.S. Patents: A Detailed Analysis

Introduction

Patents are a cornerstone of innovation, providing inventors and companies with exclusive rights to their inventions. The U.S. patent system, managed by the U.S. Patent and Trademark Office (USPTO), is complex and evolving. This article delves into the key aspects of patent scope, claims, and the broader patent landscape in the United States, using the context of a specific patent, U.S. Patent 10,159,683, as a case study.

Patent-Eligible Subject Matter

To understand the scope of any patent, it is crucial to begin with what constitutes patent-eligible subject matter. Section 101 of the Patent Act defines four categories of patentable inventions: processes, machines, manufactures, and compositions of matter[2].

Judicial Developments and Section 101

Recent judicial decisions have significantly impacted what can be patented. The Supreme Court's decisions in cases like Bilski v. Kappos, Mayo Collaborative Servs. v. Prometheus Labs., and Alice Corp. v. CLS Bank have narrowed the scope of patent-eligible subject matter. These decisions introduced broader judicially developed exceptions, particularly affecting business methods, natural phenomena, and abstract ideas[2].

The Alice/Mayo Test

The Alice/Mayo test is a two-step framework used to determine patent eligibility. First, it assesses whether the claims are directed to an ineligible concept. If not, the second step evaluates whether the claims contain an inventive concept that transforms the ineligible concept into something patentable. This test has been particularly challenging for AI and software patents, as they often involve abstract ideas or mathematical concepts[2].

Patent Claims and Scope

Patent claims are the heart of a patent, defining the scope of the invention. Two key metrics for measuring patent scope are independent claim length and independent claim count. Narrower claims, as measured by these metrics, are associated with a higher probability of grant and a shorter examination process[3].

Drafting Patent Claims

When drafting patent claims, especially those involving subjective terms, it is essential to provide numerous and meaningful examples to ensure clarity. U.S. patent law requires that claims "particularly point out" and "distinctly" claim the subject matter of the invention. This balance between clarity and the inherent limitations of language is crucial to avoid claims being found invalid as indefinite[5].

Technology Areas and Patent Trends

The USPTO classifies patents into various technology areas, which can be aggregated to analyze trends. For instance, electrical and mechanical engineering patents made up about 60% of USPTO patents in 2018, with a significant increase in electrical engineering patents driven by information and communication technologies (ICT)[4].

Case Study: U.S. Patent 10,159,683

While the specific details of U.S. Patent 10,159,683 are not provided here, a typical analysis would involve:

Patent Eligibility

  • Determine if the patent claims fall within the categories defined by Section 101.
  • Apply the Alice/Mayo test to ensure the claims are not directed to ineligible concepts.

Claim Scope

  • Analyze the independent claim length and count to understand the breadth of the patent.
  • Evaluate the clarity and specificity of the claims, ensuring they meet the requirements of 35 USC 112(b).

Technology Area

  • Identify the technology area into which the patent falls, such as electrical engineering or computer technology.
  • Assess how the patent fits into broader trends within its technology area.

Probability of Receiving a U.S. Patent

The probability of receiving a U.S. patent varies based on several factors, including the technology field, the size of the entity filing the patent, and the origin of the application. For example, utility patent applications filed by large entities may have different allowance rates compared to those filed by small entities. The USPTO's internal databases provide detailed insights into these probabilities, including first-action allowance rates, progenitor allowance rates, and family allowance rates[1].

Impact of Recent Guidance

The USPTO's 2019 Guidance on the Alice/Mayo framework has had a significant impact on patent examination processes, particularly for AI and computer-related inventions. This guidance has been perceived as lowering Section 101 barriers to patentability, leading to an increase in the allowance rate for these types of patent applications[2].

Global and Comparative Trends

Patent trends are not isolated to the U.S.; global trends also play a crucial role. The World Intellectual Property Organization (WIPO) classification system helps in comparing patent data internationally. For instance, the rise in ICT patents is a global phenomenon, reflecting the increasing importance of digital technologies[4].

Key Takeaways

  • Patent Eligibility: Understanding Section 101 and the Alice/Mayo test is crucial for determining what can be patented.
  • Claim Scope: Narrower claims are generally associated with higher grant probabilities and shorter examination processes.
  • Technology Trends: Electrical and mechanical engineering patents dominate the landscape, with ICT driving significant growth.
  • Drafting Claims: Clarity and specificity are essential when drafting patent claims, especially those involving subjective terms.
  • Global Context: Patent trends are influenced by global technological advancements and international classification systems.

FAQs

Q: What are the four categories of patentable inventions under Section 101 of the Patent Act? A: The four categories are processes, machines, manufactures, and compositions of matter[2].

Q: How does the Alice/Mayo test impact AI and software patents? A: The test often characterizes AI and software inventions as abstract ideas or mathematical concepts, making them ineligible for patents unless they contain an inventive concept[2].

Q: What metrics are used to measure patent scope? A: Independent claim length and independent claim count are commonly used metrics to measure patent scope[3].

Q: Why is clarity important in drafting patent claims? A: Clarity ensures that claims are not found invalid as indefinite, meeting the requirements of 35 USC 112(b)[5].

Q: How has the USPTO's 2019 Guidance affected patent examination processes? A: The guidance has lowered Section 101 barriers to patentability, particularly for AI and computer-related inventions, leading to an increase in allowance rates[2].

Sources

  1. Carley, M., & Hegde, D. (n.d.). What Is the Probability of Receiving a US Patent?. The Yale Journal of Law & Technology.
  2. CRS Reports. (2024). Patent-Eligible Subject Matter Reform: An Overview.
  3. SSRN. (2016). Patent Claims and Patent Scope.
  4. NCSES. (2020). Invention: U.S. and Comparative Global Trends.
  5. BIPC. (2017). Practical Advice for Drafting Patents with Subjective Claims Terms.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,159,683

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eyepoint Pharms DEXYCU KIT dexamethasone SUSPENSION;INTRAOCULAR 208912-001 Feb 9, 2018 RX Yes Yes 10,159,683 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.